atenolol has been researched along with Metabolic Syndrome in 11 studies
Atenolol: A cardioselective beta-1 adrenergic blocker possessing properties and potency similar to PROPRANOLOL, but without a negative inotropic effect.
atenolol : An ethanolamine compound having a (4-carbamoylmethylphenoxy)methyl group at the 1-position and an N-isopropyl substituent.
Metabolic Syndrome: A cluster of symptoms that are risk factors for CARDIOVASCULAR DISEASES and TYPE 2 DIABETES MELLITUS. The major components of metabolic syndrome include ABDOMINAL OBESITY; atherogenic DYSLIPIDEMIA; HYPERTENSION; HYPERGLYCEMIA; INSULIN RESISTANCE; a proinflammatory state; and a prothrombotic (THROMBOSIS) state.
| Excerpt | Relevance | Reference |
|---|---|---|
| "To comparatively estimate the time course of changes in key metabolic parameters and quality of life (QL) in patients with coronary heart disease during 4-week therapy with atenolol and amlodipine." | 9.17 | [Comparative evaluation of the impact of four-week therapy with amlodipine and atenolol on quality of life and blood lipid composition in patients with coronary heart disease associated with metabolic syndrome]. ( Bespalova, LD; Kalyuzhin, VV; Kalyuzhina, EV; Kolesnikov, RN; Pushnikova, EY; Teplyakov, AT, 2013) |
| "Combination therapy of nitrendipine and atenolol may significantly increase BW and fasting BG in overweight or obese patients with hypertension." | 9.14 | Effect of metformin on weight gain during antihypertensive treatment with a beta-blocker in Chinese patients. ( Qin, YW; Qiu, JL; Zhang, JL; Zhao, XX; Zheng, X; Zou, DJ, 2009) |
| "The objective of the present study was to explore the effect of carvedilol treatment on metabolic parameters in patients with metabolic syndrome." | 9.12 | The effect of carvedilol on metabolic parameters in patients with metabolic syndrome. ( Oguz, A; Uzunlulu, M; Yorulmaz, E, 2006) |
| "The present post-hoc analyses were aimed at: describing the prevalence of the metabolic syndrome (MS) at baseline; investigating the effect of long-term antihypertensive therapy (and separately of atenolol and lacidipine) on MS prevalence; exploring whether MS at baseline influenced changes in carotid IMT and incidence of cardiovascular events during treatment; and describing the relations between MS and new cases of diabetes developing during treatment." | 9.12 | Prevalence and incidence of the metabolic syndrome in the European Lacidipine Study on Atherosclerosis (ELSA) and its relation with carotid intima-media thickness. ( Baurecht, H; Carugo, S; Cuspidi, C; Hennig, M; Mancia, G; Tang, R; Zanchetti, A, 2007) |
| "Metabolic syndrome patients with hypertension (n=28) and a control group (n=20) were given atenolol (50 mg/day) for 4 weeks." | 7.77 | The enhanced effect of atenolol on hypertension in metabolic syndrome. ( Satou, Y; Ueno, N, 2011) |
| "To comparatively estimate the time course of changes in key metabolic parameters and quality of life (QL) in patients with coronary heart disease during 4-week therapy with atenolol and amlodipine." | 5.17 | [Comparative evaluation of the impact of four-week therapy with amlodipine and atenolol on quality of life and blood lipid composition in patients with coronary heart disease associated with metabolic syndrome]. ( Bespalova, LD; Kalyuzhin, VV; Kalyuzhina, EV; Kolesnikov, RN; Pushnikova, EY; Teplyakov, AT, 2013) |
| "Combination therapy of nitrendipine and atenolol may significantly increase BW and fasting BG in overweight or obese patients with hypertension." | 5.14 | Effect of metformin on weight gain during antihypertensive treatment with a beta-blocker in Chinese patients. ( Qin, YW; Qiu, JL; Zhang, JL; Zhao, XX; Zheng, X; Zou, DJ, 2009) |
| "The objective of the present study was to explore the effect of carvedilol treatment on metabolic parameters in patients with metabolic syndrome." | 5.12 | The effect of carvedilol on metabolic parameters in patients with metabolic syndrome. ( Oguz, A; Uzunlulu, M; Yorulmaz, E, 2006) |
| "The present post-hoc analyses were aimed at: describing the prevalence of the metabolic syndrome (MS) at baseline; investigating the effect of long-term antihypertensive therapy (and separately of atenolol and lacidipine) on MS prevalence; exploring whether MS at baseline influenced changes in carotid IMT and incidence of cardiovascular events during treatment; and describing the relations between MS and new cases of diabetes developing during treatment." | 5.12 | Prevalence and incidence of the metabolic syndrome in the European Lacidipine Study on Atherosclerosis (ELSA) and its relation with carotid intima-media thickness. ( Baurecht, H; Carugo, S; Cuspidi, C; Hennig, M; Mancia, G; Tang, R; Zanchetti, A, 2007) |
| "The aim of the Antihypertensive Treatment and Lipid Profile in a North of Sweden Efficacy Evaluation study was to compare the long-term effect of the commonly used inexpensive medication with a low-dose diuretic (hydrochlorothiazide), alone or in combination with a beta-adrenoceptor (atenolol), with that of more modern but also more expensive antihypertensive treatment with an angiotensin-II-receptor blocker (candesartan), alone or in combination with a calcium antagonist (felodipine), and to do so in newly diagnosed patients with primary hypertension." | 5.10 | Metabolic outcome during 1 year in newly detected hypertensives: results of the Antihypertensive Treatment and Lipid Profile in a North of Sweden Efficacy Evaluation (ALPINE study). ( Alaupovic, P; Carlberg, B; Lindholm, LH; Persson, M; Samuelsson, O; Svensson, A, 2003) |
| "Metabolic syndrome patients with hypertension (n=28) and a control group (n=20) were given atenolol (50 mg/day) for 4 weeks." | 3.77 | The enhanced effect of atenolol on hypertension in metabolic syndrome. ( Satou, Y; Ueno, N, 2011) |
| "Atenolol, a first-generation β-blocker, effectively reduces blood pressure, although its use in metabolic syndrome remains controversial." | 3.77 | Long-term treatment with nebivolol attenuates renal damage in Zucker diabetic fatty rats. ( Angerosa, M; Cao, G; Dominici, FP; Giani, JF; Muñoz, MC; Toblli, JE, 2011) |
| "We evaluated the effects of nebivolol, a third-generation highly selective [beta]-blocker with additional vasodilating activity, versus the traditional [beta]-blocker atenolol in controlling functional and morphological cardiovascular damage in a rat model of metabolic syndrome." | 3.76 | Cardiovascular protective effects of nebivolol in Zucker diabetic fatty rats. ( Angerosa, M; Cao, G; Dominici, F; Giani, J; Munoz, M; Rivas, C; Toblli, J, 2010) |
| "Seventy five patients with metabolic syndrome aged 40-59 years were included into an open study with parallel groups in which the following combinations of lipid lowering and antihypertensive drugs were used for sweeksinch: atorvastatin + perindopril (n=17, group 1); simvastatin + atenolol (n=17, group 2); fenofibrate + atenolol (n=21, group 3), and simvastatin + indapamide (n=20, group 4)." | 3.72 | [Effect of combined antihypertensive and lipid lowering therapy on the level of coronary risk and tissue insulin resistance in patients with metabolic syndrome]. ( Khadipash, LA; Kiseleva, NV; Kosmatova, OV; Mamedov, MN; Oganov, RG; Perova, NV, 2003) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 7 (63.64) | 29.6817 |
| 2010's | 4 (36.36) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Kalyuzhin, VV | 1 |
| Teplyakov, AT | 1 |
| Pushnikova, EY | 1 |
| Bespalova, LD | 1 |
| Kalyuzhina, EV | 1 |
| Kolesnikov, RN | 1 |
| Zhang, JL | 1 |
| Zheng, X | 1 |
| Zou, DJ | 1 |
| Qiu, JL | 1 |
| Zhao, XX | 1 |
| Qin, YW | 1 |
| Toblli, J | 1 |
| Cao, G | 2 |
| Rivas, C | 1 |
| Munoz, M | 1 |
| Giani, J | 1 |
| Dominici, F | 1 |
| Angerosa, M | 2 |
| Ueno, N | 1 |
| Satou, Y | 1 |
| Toblli, JE | 1 |
| Giani, JF | 1 |
| Muñoz, MC | 1 |
| Dominici, FP | 1 |
| Lindholm, LH | 1 |
| Persson, M | 1 |
| Alaupovic, P | 1 |
| Carlberg, B | 1 |
| Svensson, A | 1 |
| Samuelsson, O | 1 |
| Mamedov, MN | 1 |
| Perova, NV | 1 |
| Kosmatova, OV | 1 |
| Khadipash, LA | 1 |
| Kiseleva, NV | 1 |
| Oganov, RG | 1 |
| Baumgart, P | 1 |
| Uzunlulu, M | 1 |
| Oguz, A | 1 |
| Yorulmaz, E | 1 |
| Safar, ME | 1 |
| Zanchetti, A | 1 |
| Hennig, M | 1 |
| Baurecht, H | 1 |
| Tang, R | 1 |
| Cuspidi, C | 1 |
| Carugo, S | 1 |
| Mancia, G | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Effects of Antihypertensive Treatment on Cardiac Remodelling and Metabolic Profile in HIV Infected Patients: Randomized Longitudinal Study With Candesartan Versus Lercanidipine[NCT00564057] | Phase 4 | 30 participants (Anticipated) | Interventional | 2007-09-30 | Recruiting | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
5 trials available for atenolol and Metabolic Syndrome
| Article | Year |
|---|---|
[Comparative evaluation of the impact of four-week therapy with amlodipine and atenolol on quality of life and blood lipid composition in patients with coronary heart disease associated with metabolic syndrome].
Topics: Adrenergic beta-1 Receptor Antagonists; Adult; Amlodipine; Angina, Stable; Atenolol; Calcium Channel | 2013 |
Effect of metformin on weight gain during antihypertensive treatment with a beta-blocker in Chinese patients.
Topics: Adrenergic beta-Antagonists; Aged; Antihypertensive Agents; Atenolol; Blood Glucose; Body Mass Index | 2009 |
Metabolic outcome during 1 year in newly detected hypertensives: results of the Antihypertensive Treatment and Lipid Profile in a North of Sweden Efficacy Evaluation (ALPINE study).
Topics: Antihypertensive Agents; Apolipoproteins; Atenolol; Blood Glucose; Blood Pressure; Drug Therapy, Com | 2003 |
The effect of carvedilol on metabolic parameters in patients with metabolic syndrome.
Topics: Adrenergic alpha-Antagonists; Adrenergic beta-Antagonists; Adult; Anthropometry; Antihypertensive Ag | 2006 |
Prevalence and incidence of the metabolic syndrome in the European Lacidipine Study on Atherosclerosis (ELSA) and its relation with carotid intima-media thickness.
Topics: Aged; Antihypertensive Agents; Atenolol; Atherosclerosis; Calcium Channel Blockers; Carotid Arteries | 2007 |
6 other studies available for atenolol and Metabolic Syndrome
| Article | Year |
|---|---|
Cardiovascular protective effects of nebivolol in Zucker diabetic fatty rats.
Topics: Adrenergic beta-Antagonists; Animals; Aorta; Atenolol; Benzopyrans; Blood Pressure; Cardiovascular D | 2010 |
The enhanced effect of atenolol on hypertension in metabolic syndrome.
Topics: Adrenergic beta-Antagonists; Atenolol; Blood Glucose; Blood Pressure; Body Mass Index; Case-Control | 2011 |
Long-term treatment with nebivolol attenuates renal damage in Zucker diabetic fatty rats.
Topics: Adrenergic beta-1 Receptor Antagonists; Animals; Atenolol; Benzopyrans; Blood Pressure; Diabetes Mel | 2011 |
[Effect of combined antihypertensive and lipid lowering therapy on the level of coronary risk and tissue insulin resistance in patients with metabolic syndrome].
Topics: Adult; Antihypertensive Agents; Atenolol; Atorvastatin; Blood Pressure; Cholesterol, HDL; Cholestero | 2003 |
[Antihypertensive therapy: risk stratification in diabetes and cardiac diseases].
Topics: Adrenergic beta-Antagonists; Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme | 2006 |
Pulse pressure: a help in medical semiology for metabolic syndrome.
Topics: Adrenergic beta-Antagonists; Angiotensin-Converting Enzyme Inhibitors; Atenolol; Blood Pressure; Blo | 2007 |